LBL-024 combination therapy for metastatic colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new drug called LBL-024 combined with other treatments for people whose colorectal cancer has spread to other parts of the body. The goal is to see if the combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with colorectal cancer that has spread to other parts of the body.
- You have at least one tumor that can be measured by standard imaging tests.
- Your overall health is good enough to perform everyday activities (ECOG score 0-1).
- Your expected survival is at least 12 weeks.
- Your blood tests and organ function meet the trial's minimum standards.
- If you or your partner can have children, you must agree to use effective birth control during the study and for 6 months after the last dose.
- You must not have certain serious health conditions like active infections (hepatitis B or C), HIV, or autoimmune diseases that are uncontrolled.
- You must be willing to follow the study schedule and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies serplulimab (an immune-related drug) together with bevacizumab and chemotherapy to treat metastatic colorectal (colon) cancer that cannot be removed with surgery. It aims to see whether this combination improves outcomes and is safe.
This trial tests adding a new immunotherapy drug (QL1706) to standard chemotherapy plus bevacizumab for people with colorectal cancer that has spread and hasn't been treated yet. It aims to see if the combination works better than standard treatment alone.
This study tests a new combination of short-course radiation followed by two targeted drugs (fruquintinib and sintilimab) compared to standard therapy (bevacizumab and capecitabine) for people with advanced colorectal cancer who cannot tolerate strong chemotherapy. It aims to see if this gentler approach works as well or better.
This trial tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy plus bevacizumab can help people with a specific type of metastatic colorectal cancer that cannot be removed by surgery. It is for patients whose tumors are microsatellite stable (MSS) or have normal mismatch repair (pMMR).
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
This trial is testing a combination of three drugs (liposomal irinotecan, capecitabine, and bevacizumab) for people with metastatic colorectal cancer whose first-line treatment failed. The goal is to see if this combo works better as a second option.
Hear when a new Metastatic Colorectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.